Latest Sustainability News

Dalrymple Bay Infrastructure has declared its Q3-25 distribution consistent with its full-year guidance, reinforcing its commitment to stable returns backed by its key coal export terminal.

West African Resources is advancing negotiations with the Burkina Faso Government over equity interests in its Kiaka gold project, proposing alternatives to direct government ownership to boost national benefits without diluting shareholder value.

Nex Metals Explorations reported no exploration spending in Q1 FY26 but made significant strides by finalising a profit-sharing deal for its Kookynie project and entering Egypt’s Eastern Desert mining scene.

Macquarie Technology Group unveiled ambitious plans to expand its AI-optimised data centre footprint, supported by a $450 million debt facility and strong growth across its cloud, government cybersecurity, and telecom divisions.

Monadelphous has reported a record-breaking year with $2.3 billion in new contracts and a strong financial performance, underpinned by strategic acquisitions and growth in energy transition sectors.

Monadelphous Group Limited reported a robust FY25 with record contract wins and a 30% revenue surge, setting the stage for continued growth in FY26. The company’s strategic acquisitions and energy transition focus underpin its optimistic outlook.

Jameson Resources Limited has updated its Employee Share Option Plan, approved at the 2025 AGM, aiming to better incentivize and retain key personnel while aligning employee interests with shareholders.

Comms Group reported robust FY25 results driven by domestic expansion, including the strategic acquisition of TasmaNet, and strong international growth in its Global and Wholesale division.

Elixir Energy secures a $16.6 million capital raise led by Omega Oil and Gas, propelling Phase-2 of its strategic plan to unlock reserves in Queensland’s Taroom Trough.

ABx Group has successfully raised over $6 million through a share placement to fund rapid development of its Deep Leads rare earth project and ALCORE pilot plant in Tasmania.

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.

Mesoblast has achieved a landmark FDA approval for RYONCIL, the first allogeneic mesenchymal stromal cell therapy, driving strong commercial momentum and advancing a robust pipeline targeting inflammatory diseases.